← All trials
NCT05920356
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2023
- Primary completion
- Feb 14, 2026
- Completion date
- Jan 13, 2031
- First posted
- Jun 27, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 750
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.